|
Main
|
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
8 February 2021 |
|
Main ID: |
NCT03019679 |
|
Date of registration:
|
11/01/2017 |
|
Prospective Registration:
|
No |
|
Primary sponsor: |
|
|
Public title:
|
Serum Endocan Levels in Polycystic Ovary Syndrome
|
|
Scientific title:
|
Serum Endocan Levels in Polycystic Ovary Syndrome: a Possible Marker of Angiogenic Dysfunction |
|
Date of first enrolment:
|
January 2017 |
|
Target sample size:
|
175 |
|
Recruitment status: |
Completed |
|
URL:
|
https://clinicaltrials.gov/show/NCT03019679 |
|
Study type:
|
Observational |
|
Study design:
|
|
|
Phase:
|
|
|
|
Countries of recruitment
|
|
Turkey
| | | | | | | |
|
Contacts
|
|
Name:
|
Esra Laloglu, M.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Erzurum Halk Sagligi Laboratuvari |
|
|
Name:
|
Ilhan B Delibas, M.D. |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Gaziosmanpasa University Department of Obstetrics and Gynecology |
| |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- 18 to 45 years
- Patients diagnosed with PCOS according to Rotterdam criteris (for the study group)
- Patients without PCOS and menstrual irregularities (for the control group)
- Absence of significant abnormalities on physical examination except hirsutism
- No lipid lowering, hypoglycemic, antihypertensive or hormone replacement therapy
- Normal thyroid function and prolactin level
- Absence of history or evidence of metabolic, cardiovascular, respiratory or hepatic
disease
Exclusion Criteria:
- Pregnant
- Ovarian tumors
- Endocrine diseases (Cushing disease, 21-Hydroxylase enzyme deficiency, thyroid
dysfunction,hyperprolactinemia,diabetes)
- Chronic diseases (renal insufficiency, cardiovascular, hepatic disease)
- Oral contraceptive use, anti-androgenic,glucocorticoid, anti-hypertansive-
anti-diabetic drug use
- Smoking or alcohol use
Age minimum:
18 Years
Age maximum:
45 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Polycystic Ovary Syndrome
|
|
Primary Outcome(s)
|
|
Serum endocan level and its relationship with Polycystic Ovary Syndrome
[Time Frame: 3 months]
|
|
Secondary ID(s)
|
|
GaziosmanpasaU
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|
Results
|
|
Results available:
|
|
|
Date Posted:
|
|
|
Date Completed:
|
|
|
URL:
|
|
|
|